Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Contributed by: Business Wire

Logo

Tags

Other Manufacturing

Research

Neurology

Manufacturing

Biotechnology

Other Health

Health

Pharmaceutical

Science

Teva

More Like This

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Ocrelizumab approved as an injection to treat multiple sclerosis in adults

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars